{"nctId":"NCT00331864","briefTitle":"SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration","startDateStruct":{"date":"2006-04"},"conditions":["Age Related Macular Degeneration","Choroidal Neovascularization"],"count":531,"armGroups":[{"label":"Ranibizumab","type":"EXPERIMENTAL","interventionNames":["Drug: Ranibizumab"]}],"interventions":[{"name":"Ranibizumab","otherNames":["rhuFab V2"]}],"eligibilityModule":{"eligibilityCriteria":"Patients who participated in this study included those who had completed participation in the study CRFB002A2301 (ANCHOR; NCT00061594), newly diagnosed patients, as well as previously diagnosed patients who had had recent disease progression.\n\nInclusion Criteria:\n\n* Male or female patients \\> 50 years of age\n* Diagnosis of active primary or recurrent CNV secondary to AMD, including those with predominantly classic, minimally classic or occult lesions with no classic component\n* The total area of CNV (including both classic and occult components) encompassed within the lesion must be \\>= 50% of the total lesion area\n* The total lesion area must be \\<= 12 disc areas\n* Patients who have a BCVA (best corrected visual acuity) score between 73 and 24 letters, inclusive, in the study eye using ETDRS-like (Early Treatment of Diabetic Retinopathy Study) grading charts (approximately 20/40 to 20/320)\n\nExclusion Criteria:\n\n* Patients who have a BCVA of \\< 34 letters in both eyes (legally blind is defined as bilateral vision below 20/200 or less than 34 letters)\n* Laser photocoagulation, treatment with intravitreal steroids, verteporfin photo dynamic therapy or pegaptanib sodium in the study eye within 30 days preceding Day 1\n* Previous participation in a clinical trial (for either eye) involving anti-angiogenic drugs (pegaptanib, ranibizumab, anecortave acetate, protein kinase C inhibitors, etc.)\n\nOther protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Patients With Ocular Adverse Events (AEs) in the Study Eye","description":"Percentage of patients with ocular adverse events in the study eye over the one year (12 month) treatment period.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.5","spread":null},{"groupId":"OG001","value":"38.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change in Best Corrected Visual Acuity (BCVA) of the Study Eye From Baseline to Month 3","description":"BCVA was assessed using best correction determined from protocol refraction. BCVA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at an initial testing distance of 4 meters.\n\nBCVA is measured by the number of letters a patient could correctly read on an eye chart; hence an increased score indicates improvement in acuity.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.2","spread":"12.11"},{"groupId":"OG001","value":"47.2","spread":"22.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":"11.12"},{"groupId":"OG001","value":"1.9","spread":"9.26"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Best Corrected Visual Acuity (BCVA) of the Study Eye From Baseline to Month 12","description":"BCVA was assessed using best correction determined from protocol refraction. BCVA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at an initial testing distance of 4 meters.\n\nBCVA is measured by the number of letters a patient could correctly read on an eye chart; hence an increased score indicates improvement in acuity.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.2","spread":"12.11"},{"groupId":"OG001","value":"47.2","spread":"22.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"13.89"},{"groupId":"OG001","value":"1.6","spread":"8.66"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Central Retinal Thickness of the Study Eye From Baseline to Month 3","description":"Central retinal thickness was assessed using optical coherence tomography (OCT). OCT imaging was performed by trained personnel at each site using the Zeiss Stratus OCT™ 3 with version A6.1 (or more recent) software. Analysis of the OCT images was performed by the investigator. A negative number indicates improvement (reduced thickness).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"339.6","spread":"109.38"},{"groupId":"OG001","value":"214.1","spread":"64.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-101.1","spread":"115.69"},{"groupId":"OG001","value":"36.3","spread":"72.96"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Central Retinal Thickness of the Study Eye From Baseline to Month 12","description":"Central retinal thickness was assessed using optical coherence tomography (OCT). OCT imaging was performed by trained personnel at each site using the Zeiss Stratus OCT™ 3 with version A6.1 (or more recent) software. Analysis of the OCT images was performed by the investigator. A negative number indicates improvement (reduced thickness).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"339.6","spread":"109.38"},{"groupId":"OG001","value":"214.1","spread":"64.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-91.5","spread":"115.47"},{"groupId":"OG001","value":"39.3","spread":"84.61"}]}]}]},{"type":"SECONDARY","title":"Time to the First Retreatment After Month 2","description":"Time to first re-treatment is calculated as time difference in months starting from Month 2 until the month of first re-treatment.\n\nCriteria for re-treatment:\n\n* a \\>5 letter decrease in BCVA (determined using EDRS charts) based upon the highest visual acuity score from any prior scheduled study visit (Months 0, 1, 2 or 3)\n* a \\>100 µm increase in central retinal thickness (determined using OCT) from the thinnest measurement from any prior scheduled study visit (Months 0, 1, 2 or 3)","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Number of Treatments","description":"Total number of treatments administered during the entire treatment period (Month 0 to 11).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"2.37"},{"groupId":"OG001","value":"1.1","spread":"2.29"}]}]}]},{"type":"PRIMARY","title":"Percentage of Patients With Targeted Grade 3 Adverse Events (AEs) in the Study Eye","description":"Grade 3 targeted AEs included:\n\n* 4+ ocular inflammation or 2-3+ ocular inflammation failing to decrease to ≤ 1+ within 30 days\n* ≥ 30 letter decrease in BCVA that developed within 14 days of ranibizumab injection\n* sustained (\\>15 minutes) loss of light perception due to elevated intraocular pressure (IOP) or a \\>20 mm Hg change in IOP persisting longer than 14 days\n* new retinal tear or detachment involving the macula\n* new vitreous hemorrhage \\>2+ severity not resolving within 14 days\n* new or increase of previous retinal hemorrhage \\>1 disc area in size and involving the fovea","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":80,"n":513},"commonTop":["Visual acuity reduced (Study eye)","Retinal haemorrhage (Study eye)","Intraocular pressure increased (Study eye)","Conjunctival haemorrhage (Study eye)","Visual acuity reduced (Fellow eye)"]}}}